

Different Strategies to Control the Renin-Angiotensin System

Bibliography of One Hundred Key Papers

selected by **Roberto Ferrari, MD, PhD**

*Chair of Cardiology - University of Ferrara - and Cardiovascular Research Center "Salvatore Maugeri" Foundation
Gussago - Brescia - ITALY*

-
- AIRE Study Group.** *Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure.*
Lancet. 1993;342:821-828.
-
- Anand IS, Kalra GS, Ferrari R, Wahi PL, Harris P, Poole-Wilson PA.** *Enalapril as initial and sole treatment in severe chronic heart failure with sodium retention.*
Int J Cardiol. 1990;28:341-346.
-
- Antony I, Lerebours G, Nitenberg A.** *Angiotensin-converting enzyme inhibition restores flow-dependent and cold pressor test-induced dilations in coronary arteries of hypertensive patients.*
Circulation. 1996;94:3115-3122.
-
- Atlas SA, Case DB, Sealey JE, Laragh JH, Mckinstry DN.** *Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis.*
Hypertension. 1979;1:274-280.
-
- Bachetti T, Comini L, Cargnoni A, Curello S, Ferrari R.** *ACE-inhibition with quinapril modulates the nitric oxide pathway in normotensive rats.*
J Mol Cell Cardiol. 2001;33:395-403.
-
- Bouaziz H, Joulin Y, Safar M, Benetos A.** *Effects of bradykinin B₂ receptor antagonism on the hypotensive effects of ACE inhibition.*
Br J Pharmacol. 1994;113:717-722.
-
- Brown NJ, Vaughan DG.** *Angiotensin-converting enzyme inhibitors.*
Circulation. 1998;97:1411-1420.
-
- Cambien F, Costerousse O, Tiret L, et al.** *Plasma level and gene polymorphism of angiotensin converting enzyme in relation to myocardial infarction.*
Circulation. 1994;90:669-676.
-
- Cambien F, Poirier O, Lecerf L, et al.** *Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction.*
Nature. 1992;359:641-644.
-
- Campbell DJ, Kladis A, Duncan AM.** *Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides.*
Hypertension. 1994;23:439-449.
-

Bibliography of One Hundred Key Papers

- Case DB, Atlas SA, Laragh JH, Sullivan PA, Sealey JE. *Use of first-dose response or plasma renin activity to predict the long-term effect of captopril: identification of triphasic pattern of blood pressure response.*
J Cardiovasc Pharmacol. 1980;2:339-346.
-
- Cohn JN, Johnson G, Ziesche J, et al. *A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.*
N Engl J Med. 1991;325:303-310.
-
- CONSENSUS Trial Study Group. *Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).*
N Engl J Med. 1987;316:1429-1435.
-
- Cushman DW, Cheung HS. *Concentrations of angiotensin-converting enzyme in tissues of the rat.*
Biochim Biophys Acta. 1971;20:261-265.
-
- Danser AH, de Lannoy LM, Saxena P, Schalekamp MADH. *Chymase does not contribute to angiotensin I-II conversion in the interstitial fluid.*
Nature. 2001;409:822-823.
-
- Danser AH, Schalekamp MA. *Is there an internal cardiac renin-angiotensin system?*
Heart. 1996;76:28-32.
-
- Danser AH, Schalekamp MA, Bax WA, van den Brink AM, Saxena PR, Riegger GA, Schunkert H. *Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism.*
Circulation. 1995;92:1387-1388.
-
- Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ. *Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease.*
Circulation. 1996;94:2756-2767.
-
- Dunn GF, Oigman W, Ventura HO, Messerli FH, Kobrin I, Frolich ED. *Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension.*
Am J Cardiol. 1984;53:105-108.
-
- Dusing R, Kaiser G, Wagner S, et al. *Baroreflex setting and sensitivity in normal subjects: effects of pharmacologic inhibition of the angiotensin I converting enzyme.*
Am J Cardiol. 1987;59:50-54.
-
- Fabris B, Jackson B, Cubela R, Mendelsohn FAO, Johnston CI. *Angiotensin converting enzyme in the rat heart: studies of its inhibition in vitro and ex vivo.*
Clin Exp Pharmacol Physiol. 1989;16:309-313.
-
- Fabris B, Jackson B, Kohzuki M, Perich R, Johnston CI. *Increased cardiac angiotensin-converting enzyme in rats with chronic heart failure.*
Clin Exp Pharmacol Physiol. 1990;17:309-314.
-
- Fagard R, Amery A, Reybrouck T, Lijnen P, Billiet L. *Acute and chronic systemic and hemodynamic effects of angiotensin converting enzyme inhibition with captopril in hypertensive patients.*
Am J Cardiol. 1980;46:295-300.
-
- Falkenhahn M, Franke F, Bohle RM, et al. *Cellular distribution of angiotensin-converting enzyme after myocardial infarction.*
Hypertension. 1995;25:219-226.
-
- Farber HW, Center DM, Rounds S, Danilov SM. *Components of the angiotensin system cause release of neutrophil chemoattractant from cultured bovine and human endothelial cells.*
Eur Heart J. 1990;11(suppl B):100-107.
-



-
- Ferrari R.** *Effect of ACE inhibition on myocardial ischaemia.*
Eur Heart J Suppl. 1998;19(suppl J):430-435.
-
- Ferrari R, Bachetti T, Guardigli G, Ceconi C.** *Bradykinin and coronary artery disease.*
Eur Heart J. 200;2:H14-H19.
-
- Ferrari R, Ceconi C, Curello S, Pepi P, Mazzeletti A, Visioli O.** *Cardioprotective effect of angiotensin-converting enzyme inhibitors in patients with coronary artery disease.*
Cardiovasc Drugs Ther. 1996;10:623-629.
-
- Flather MD, Yusuf S, Kober L, et al.** *Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients.*
Lancet. 2000;355:1575-1581.
-
- Fox KM, Henderson JR, Bertrand ME, Ferrari R, Remme WJ, Simoons ML.** *The European trial on reduction of cardiac events with perindopril in stable coronary artery diseases (EUROPA).*
Eur Heart J. 1999;19:52-55.
-
- Freis ED, Materson BJ, Flamenbaum W.** *Comparison of propranolol or hydrochlorothiazide alone for treatment of hypertension III: evaluation of the renin-angiotensin system.*
Am J Med. 1983;74:1029-1041.
-
- Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.** *GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction.*
Lancet. 1994;343:1115-1122.
-
- Harris EL, Phelan EL, Thompson CM, Millar JA, Grigor MR.** *Heart mass and blood pressure have separate genetic determinants in the New Zealand genetically hypertensive (GH) rat.*
J Hypertens. 1995;13:397-404.
-
- Heymes C, Swynghedauw B, Chevalier B.** *Activation of angiotensinogen and angiotensin-converting enzyme gene expression in the left ventricle of senescent rats.*
Circulation. 1994;90:1328-1333.
-
- Hirsch AT, Talsness CE, Schunkert H, Paul M, Dzau VJ.** *Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure.*
Circ Res. 1991;69:475-482.
-
- Hokimoto S, Yasue H, Fujimoto K, et al.** *Expression of angiotensin-converting enzyme in remaining viable myocytes of human ventricles after myocardial infarction.*
Circulation. 1996;94:1513-1518.
-
- Hollenberg NK, Meggs LG, Williams GH, Katz J, Garnie JD, Harrington DP.** *Sodium intake and renal responses to captopril in normal man and in essential hypertension.*
Kidney Int. 1981;20:240-245.
-
- Hornig B, Kohler C, Drexler H.** *Role of bradykinin in mediating vascular effects of ACE-inhibitors in humans.*
Circulation. 1997;95:1115-1118.
-
- ISIS-4 Collaborative Group.** *ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction.*
Lancet. 1995;345: 669-685.
-

Bibliography of One Hundred Key Papers

-
- Iwai N, Ohmichi N, Nakamura Y, Kinoshita M.** DD genotype of the angiotensin-converting enzyme gene is a risk factor for left ventricular hypertrophy.
Circulation. 1994;90:2622-2628.
-
- Jacob HJ, Lindpaintner K, Lincoln SE, eds.** Genetic mapping of a gene causing hypertension in the stroke-prone spontaneously hypertensive rat.
Cell. 1991;67:213-224.
-
- Johnston CI, Millar JA, McGrath BP, Matthews PG.** Long-term effects of captopril (SQ-14225) on blood pressure and hormone levels in essential hypertension.
Lancet. 1979;2:493-496.
-
- Kannel WB, Gordon T, Castelli WP, Margolis JR.** Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease: the Framingham Study.
Ann Intern Med. 1970;72:813-822.
-
- Kober L, Torp-Pederson C, Carlsen JE, et al, for the Trandolapril Cardiac Evaluation (TRACE) Study Group.** A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction.
N Engl J Med. 1995;333:1670-1676.
-
- Kromer EP, Riegger GA.** Effect of long-term angiotensin converting enzyme inhibition on myocardial hypertrophy in experimental aortic stenosis in the rat.
Am J Cardiol. 1988;62:161-163.
-
- Latini R, Maggioni AP, Flather M, Sleight P, Tognoni G.** ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials.
Circulation. 1995;92:3132-3137.
-
- Lee YA, Liang CS, Lee MA, Lindpaintner K.** Local stress, not systemic factors, regulate gene expression of the cardiac renin-angiotensin system in vivo: a comprehensive study of all its components in the dog.
Proc Natl Acad Sci USA. 1996;93:11035-11040.
-
- Lees RS, Pitt B, Chan RC, et al.** Baseline clinical and angiographic data in the quinapril ischemic event (QUIET) trial.
Am J Cardiol. 1996;78:1011-1016.
-
- Lewis EJ, Hunsicker LG, Bain RP, Rohde RD.** The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.
N Engl J Med. 1993;329:1456-1462.
-
- Lijnen P, Staessen J, Fagard R, Amery A.** Increase in plasma aldosterone during prolonged captopril treatment.
Am J Cardiol. 1982;49:1561-1563.
-
- Lindholm LH, Ibsen H, Dahlof B, et al.** Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol.
Lancet. 2002;359:1004-1010.
-
- Lindpaintner K, Lee M, Larson MG, et al.** Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass.
N Engl J Med. 1996;334:1023-1028.
-
- Linz W, Scholkens BA, Ganten D.** Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats.
Clin Exp Hypertens. 1989;11:1325-1350.
-



-
- Lund-Johansen P, Omvik P.** *Long-term haemodynamic effects of enalapril (alone and in combination with hydrochlorothiazide) at rest and during exercise in essential hypertension.*
J Hypertens. 1984;2:49-50.
-
- Luskutoff DJ, Sawdey M, Mimuro J.** *Type I plasminogen activator inhibitor.*
Prog Hemost Thromb. 1989;9:87-115.
-
- Lyall F, Morton JJ, Gillespie D.** *Angiotensin II stimulates c-jun expression in cultured vascular smooth muscle cells: superinduction by emetine.*
Eur J Intern Med. 1992;2:271-273.
-
- Magrini F, Reggiani P, Roberts N, Meazza R, Ciulls M, Zanchetti A.** *Effects of angiotensin and angiotensin blockade on coronary circulation and coronary reserve.*
Am J Med. 1988;84:55-60.
-
- Mancini GBJ, Henry GC, Macaya C, et al.** *Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND study.*
Circulation. 1996;94:258-265.
-
- Materson BJ, Reda DJ, Cushman WC, et al.** *Single drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo.*
N Engl J Med. 1993;328:914-921.
-
- McAlpine HM, Morton JJ, Leckie B, Rumley A, Gillen G, Dargie HJ.** *Neuroendocrine activation after acute myocardial infarction.*
Br Heart J. 1988;60:117-124.
-
- Mira ML, Silva MM, Manso CF.** *The scavenging of oxygen free radicals by angiotensin converting enzyme inhibitors: the importance of the sulfhydryl group in the chemical structure of the compounds.*
Ann NY Acad Sci. 1994;723:439-441.
-
- Montgomery HE, Clarkson P, Dollery CM, et al.** *Association of the angiotensin converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training.*
Circulation. 1997;96:741-747.
-
- Moroi M, Zhang L, Yasuda T, Virmani R, Gold HK, Fishman MC, Huang PL.** *Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice.*
J Clin Invest. 1998;101:1225-1232.
-
- Moser M.** *Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonist and calcium channel blocking agents: a review of potential benefits and possible adverse reactions.*
J Am Coll Cardiol. 1997;29:1414-1421.
-
- Muiesan G, Alicandri CL, Agabiti Rosei E, et al.** *Angiotensin-converting enzyme inhibition, catecholamines and hemodynamics in essential hypertension.*
Am J Cardiol. 1982;49:1420-1424.
-
- Naftilan AJ, Gilliland GK, Eldrige CS, Kraft AS.** *Induction of the proto-oncogene c-jun by angiotensin II.*
Mol Cell Biol. 1990;10:5536-5540.
-
- Nicolosi L, for the GISSI-3 Investigators.** *The GISSI-3 echocardiographic study on the effects of lisinopril, nitrates and their combination on left ventricular remodelling in six-week survivors of acute myocardial infarction.*
Eur Heart J. 1994;15:327. Abstract.
-

Bibliography of One Hundred Key Papers

- Ohmichi N, Iwai N, Maeda K, et al.** *Genetic basis of left ventricular remodelling after myocardial infarction.*
Int J Cardiol. 1996;53:265-272.
-
- Olson JA Jr, Shiverick KT, Ogilvie S, Buih WC, Raizada MK.** *Angiotensin-II induces secretion of plasminogen activator inhibitor I and a tissue metalloprotease inhibitor-related protein from rat brain astrocytes.*
Neurobiology. 1991;88:1928-1932.
-
- Paquet JL, Baudouin-Legros M, Brunelle G, Meyer P.** *Angiotensin II-induced proliferation of aortic myocytes in spontaneously hypertensive rats.*
J Hypertens. 1990;8:565-572.
-
- Pfeffer MA, Braunwald E, Moya LA, et al.** *Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction.*
N Engl J Med. 1992;327:669-677.
-
- Pfeffer MA, Damanski EM, Rosenberg Y, et al.** *Prevention of events with angiotensin-converting enzyme inhibition (The PEACE Study design).*
Am J Cardiol. 1998;82:25-30.
-
- Pieruzzi F, Abassi ZA, Keiser HR.** *Expression of renin-angiotensin system components in the heart, kidneys, and lungs of rats with experimental heart failure.*
Circulation. 1995;92:3105-3112.
-
- Pinto YM, van Gilst WH, Kingma JH, Schunkert H.** *The deletion-type allele of the angiotensin converting enzyme gene is associated with progressive ventricular dilatation after anterior myocardial infarction.*
J Am Coll Cardiol. 1995;25:1622-1626.
-
- Pool JL, Gennari J, Goldstein R, et al.** *Controlled multicenter study of antihypertensive effects of lisinopril, hydrochlorothiazide, and lisinopril plus hydrochlorothiazide in the treatment of 394 patients with mild to moderate essential hypertension.*
J Cardiovasc Pharmacol. 1987;3:36-42.
-
- No authors listed.** *PREAMI: Perindopril and Remodelling in Elderly with Acute Myocardial Infarction: study rationale and design.*
Cardiovasc Drugs Ther. 2000;14:671-679.
-
- PROGRESS Collaborative Group.** *Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack.*
Lancet. 2001;358:1033-1041.
-
- Rakugi H, Jacob HJ, Krieger JE, Ingelfinger JR, Pratt RE.** *Vascular injury induces angiotensinogen gene expression in the media and neointima.*
Circulation. 1993;87:283-290.
-
- Rakugi H, Wang DS, Dzau YJ.** *Potential importance of tissue angiotensin converting enzyme inhibition in preventing neointima formation.*
Circulation. 1994;90:449-455.
-
- Ravid M, Savin H, Jutrin I, Bental T, Lang R, Lishner M.** *Long-term effect of ACE inhibition on development of nephropathy in diabetes mellitus type II.*
Kidney Int. 1994;45:161-164.
-



-
- Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F.** *An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels.* **J Clin Invest.** 1990;86:1343-1346.
-
- Ruzicka M, Skarda V, Leenen FH.** *Effects of ACE-inhibitors on circulating versus cardiac angiotensin II in volume overload-induced cardiac hypertrophy in rats.* **Circulation.** 1995;92:3568-3573.
-
- Sadoshima J, Xu Y, Slayter HS, Izumo S.** *Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro.* **Cell.** 1993;75:977-984.
-
- Schmieder RE, Martus P, Klingbeil A.** *Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies.* **JAMA.** 1996;275:1507-1513.
-
- Schunkert H.** *Polymorphism of the angiotensin converting enzyme gene and cardiovascular disease.* **J Mol Med.** 1997;75:867-875.
-
- Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein CS, Lorell BH.** *Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation.* **J Clin Invest.** 1990;86:1913-1920.
-
- Schunkert H, Hense HW, Danser J, Muscholl M, Luchmer A, Riegger AJG.** *Association between circulating components of the renin angiotensin aldosterone system and left ventricular mass.* **Br Heart J.** 1997;77:24-31.
-
- Scicli AG, Carretero OA.** *Bradykinin-dependent mechanisms contributing to the CV effects of ACE inhibitors.* **J Myocard Isch.** 1995;7(suppl 1):21-33.
-
- Shai SY, Fishel RS, Martin BM, Berk BC, Bernstein KE.** *Bovine angiotensin converting enzyme cDNA cloning and regulation. Increased expression during endothelial cell growth arrest.* **Circ Res.** 1992;70:1274-1281.
-
- Simon AC, Levenson JA, Bouthier J, Maarek B, Safar ME.** *Effects of acute and chronic angiotensin enzyme inhibition on large arteries in human hypertension.* **J Cardiovasc Pharmacol.** 1985;7:45-51.
-
- Su JB, Barbe F, Crozatier B, Campbell DJ, Hittinger L.** *Increased bradykinin levels accompany the hemodynamic response to acute inhibition of angiotensin-converting enzyme in dogs with heart failure.* **J Cardiovasc Pharmacol.** 1999;34:700-710.
-
- Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H, for the CONSENSUS II Study Group.** *Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction.* **N Engl J Med.** 1992;327:678-684.
-
- Tarazi RC, Bravo EL, Fouad FM, Omvik P, Cody RJ.** *Hemodynamic and volume changes associated with captopril.* **Hypertension.** 1980;2:576-585.
-

Bibliography of One Hundred Key Papers

The Heart Outcomes Prevention Evaluation Study Investigators.

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

N Engl J Med. 2000;342:145-153.

The SOLVD Investigators.

Effect of enalapril on mortality and development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.

N Engl J Med. 1992;327:685-691.

The SOLVD Investigators.

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

N Engl J Med. 1991;325:293-302.

Todd PA, Heel RC.

Enalapril: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension and congestive heart failure.

Drugs. 1986;31:198-248.

Urata H, Healy B, Stewart RW, Bumpus FM, Husain A.

Angiotensin II-forming pathways in normal and failing human hearts.

Circ Res. 1990;66:883-890.

Veterans Administration Co-operative Study Group of Antihypertensive Agents.

Racial differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide.

Br J Clin Pharmacol. 1982;14:97-101.

Weber KT, Brilla CG.

Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system.

Circulation. 1991;83:1849-1865.

Weber KT, Sun Y, Guntaka RV.

Rebuilding and remodeling following myocardial infarction. The Good, the Bad, and the Ugly of tissue repair.

Dialogues Cardiovasc Med. 1999;4:3-19.

Yamada H, Fabris B, Allen AM, Jackson B, Johnston CI, Mendelsohn AO.

Localisation of angiotensin converting enzyme in rat heart.

Circ Res. 1991;68:141-149.

Yusuf S, Pepine CJ, Garces C, et al.

Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions.

Lancet. 1992;340:1173-1178.

Zimmerman BG, Sybertz EJ, Wong PC.

Interaction between sympathetic and renin-angiotensin system.

Hypertension. 1984;2:581-587.
